• Opinion
• Healthcare

Perth’s billionaire set is piling into this little-known medtech

The value of West Australian nerve repair biotech Orthocell has doubled since September as it beefs up its shareholder bases and prepares to break into the US.

• Dec 3, 2024
• Michael Smith

• Street Talk

ReNerve kicks off IPO roadshow, points to market darling Orthocell

ReNerve reckons its NervAlign Nerve Cuff is a lower cost, more effective and easier to use treatment for Peripheral Nerve Injury (PNI).

• Oct 24, 2024
• Sarah Thompson, Kanika Sood and Emma Rapaport

• Street Talk

Bell Potter launches placement for Orthocell

ASX-listed regenerative medicine company Orthocell is seeking to raise $10 million in a placement of new shares to investors. 

• May 28, 2019
• Sarah Thompson and Anthony Macdonald

Biotech stocks to get the heart racing … or slowing

Notoriously volatile and tricky to pick, biotechnology stocks gave nimble investors plenty of opportunity to outperform blue chips in 2015 and are set to provide some wild rides in 2016 too.

• Updated Jan 7, 2016
• Jessica Sier

• Market Wrap

Patent success a good sign for Orthocell

From an operational sense, Orthocell has been quick to slip into gear after only listing on the ASX in August. And Foster Stockbroking likes the look of Orthocell, attributing a speculative “buy” recommendation to the stock.

• Updated Sep 30, 2014
• Trevor Hoey

• Shares

Eight stocks to watch

We name some recently listed stocks that analysts The Australian Financial Review spoke to suggested are worth a closer look.

• Updated Jul 5, 2014
• Tony Featherstone